1 week Ago By ABMN Staff
KLP Kapitalforvaltning AS acquired a new stake in shares of Disc Medicine, Inc. ( NASDAQ:IRON – Free Report ) during the fourth quarter, Holdings Channel reports. The fund acquired 3,700 shares of the company’s stock, valued at approximately $235,000.
Several other hedge funds also recently added to or reduced their stakes in IRON. Teacher Retirement System of Texas grew its stake in Disc Medicine by 8.9% in the fourth quarter.
Teacher Retirement System of Texas now owns 4,857 shares of the company’s stock worth $308,000 after purchasing an additional 396 shares in the last quarter. China Universal Asset Management Co. Ltd.
lifted its holdings in Disc Medicine by 10.4% during the 4th quarter. China Universal Asset Management Co.
Ltd. now owns 6,310 shares of the company’s stock worth $400,000 after buying an additional 593 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Disc Medicine by 2.
7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock worth $1,428,000 after acquiring an additional 771 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Disc Medicine by 5.
7% in the 4th quarter. Rhumbline Advisers now owns 29,036 shares of the company’s stock valued at $1,841,000 after acquiring an additional 1,553 shares during the last quarter. Finally, JPMorgan Chase & Co.
raised its position in shares of Disc Medicine by 16.1% during the 3rd quarter. JPMorgan Chase & Co.
now owns 16,255 shares of the company’s stock valued at $799,000 after acquiring an additional 2,257 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.
Disc Medicine Trading Down 4.9 % NASDAQ IRON opened at $39.20 on Tuesday.
The company has a 50-day moving average price of $53.11 and a two-hundred day moving average price of $56.09.
Disc Medicine, Inc. has a 52 week low of $25.64 and a 52 week high of $68.
73. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -9.
85 and a beta of 0.77. Wall Street Analysts Forecast Growth IRON has been the subject of a number of research reports.
HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Tuesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and issued a $85.
00 price target on shares of Disc Medicine in a report on Friday, March 7th. Scotiabank increased their price objective on shares of Disc Medicine from $73.00 to $75.
00 and gave the stock a “sector outperform” rating in a research note on Monday, March 3rd. Stifel Nicolaus raised their target price on shares of Disc Medicine from $90.00 to $94.
00 and gave the stock a “buy” rating in a report on Friday, January 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $90.00 target price (up from $83.
00) on shares of Disc Medicine in a report on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.
com, Disc Medicine has an average rating of “Buy” and a consensus target price of $93.80. Get Our Latest Report on Disc Medicine Insider Activity at Disc Medicine In other news, Director Mona Ashiya sold 10,011 shares of the company’s stock in a transaction that occurred on Friday, March 21st.
The shares were sold at an average price of $54.00, for a total value of $540,594.00.
Following the completion of the sale, the director now directly owns 187,297 shares of the company’s stock, valued at approximately $10,114,038. This represents a 5.07 % decrease in their position.
The sale was disclosed in a legal filing with the SEC, which is accessible through this link . Also, insider Pamela Stephenson sold 3,137 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.
58, for a total transaction of $171,217.46. Following the completion of the transaction, the insider now owns 69,529 shares of the company’s stock, valued at $3,794,892.
82. This trade represents a 4.32 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders sold 361,690 shares of company stock worth $19,648,094 in the last 90 days. Corporate insiders own 4.
24% of the company’s stock. Disc Medicine Company Profile ( Free Report ) Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Featured Articles Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. ( NASDAQ:IRON – Free Report ).
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter ..
